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Abstract: Adolescence is a period in human 
development during which people are more 
prone to risk-taking and less prone to impulse 
control. Some young people experiment with 
both licit and illicit substances during this time 
(alcohol, tobacco, cannabis and other drugs) and 
this can have an impact on their behaviour, their 
relationships with others and their functioning in 
society. For the few who develop substance use 
disorders, family has an important role in 
addressing this issue. Our report focuses on 
multidimensional family therapy — a process 
that includes the young person, their family and 
their environment. Initial experiments show that 
this holistic approach delivers promising results 
during therapy and that these can last after the 
treatment ends.
Five main studies carried out in the United States 
and the European Union are the starting point for 
our analysis and discussions. While initial results 
provided by the studies are promising, it appears 
important to assure implementation fidelity and 
family adherence, which in the most critical 
cases can be difficult. Furthermore, the relatively 
high cost of such treatment must be considered 
before recommending its general use. 
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communication and problem-solving using multi-participant 
family sessions; and (4) the extrafamilial domain fosters family 
competency within all social systems in which the adolescent 
participates (e.g. school, the juvenile justice system, 
recreational facilities). Therapists meet alone with the 
adolescent, alone with the parent(s) and/or conjointly with the 
adolescent and parent(s), depending on the treatment domain 
and specific problem being addressed.
MDFT is a manualised intervention composed of four 
interdependent modules: (1) the adolescent module 
addresses developmental issues such as identity formation, 
peer relations, prosocial involvement and drug use 
consequences; (2) the parent module enhances parenting 
skills in the areas of monitoring and limit-setting, rebuilding 
parents’ emotional bonds with the child and fostering parental 
participation in the teenager’s life outside the family; (3) the 
family module facilitates changes in family relationships by 
helping family members to develop social and communication 
skills; and (4) the extrafamilial module seeks to establish 
positive relationships within all social systems in which the 
adolescent participates (e.g. family, school, peer group, 
community).
The overall intervention is administered in three stages. 
Stage 1 comprises a comprehensive assessment of problem 
areas to identify which of the multiple domains of the 
adolescent’s life would benefit from intervention, to set goals 
and to identify specific areas treatment should target. Stage 
2, the treatment stage, aims to promote and improve 
appropriate skills such as communication and problem-
solving skills within and across the four domains. Stage 3 
focuses on encouraging the family to maintain progress and 
to practise new behaviours in current and future real-world 
situations.
MDFT has been recognised and recommended by several 
agencies and organisations in the USA as a comprehensive, 
multicomponent, theoretically derived and empirically 
supported treatment for adolescent drug misuse. First 
implemented in 1985, the programme has been used at nearly 
40 sites in 11 states among young people from diverse ethnic 
and socioeconomic backgrounds, in urban, suburban and rural 
settings, and in a variety of contexts (e.g. in home and 
residential treatment programmes, schools, detention centres, 
hospitals and mental health centres as well as with young 
people serving court-mandated programmes as an alternative 
to detention). MDFT is currently being implemented in several 
European countries, including Belgium, Germany, France, the 
Netherlands and Switzerland. These countries are involved in 
a collaborative evaluation study known as INCANT 
(International Cannabis Need of Treatment Project; see more 
at www.incant.eu, which includes a randomised controlled 
trial of MDFT, funded under Europe’s Action Plan for Cannabis 
Research).
I Background
I Description of the condition
The majority of individuals who develop substance use 
problems report that their drug use began in adolescence (von 
Sydow et al., 2001).
In Europe, among young adults (15–34 years), lifetime 
prevalence of use is 32 % for cannabis, 6 % for cocaine, 5 % 
for amphetamines and 6 % for ecstasy (EMCDDA, 2011). In 
the 2011 European School Survey Project on Alcohol and 
Other Drugs (ESPAD), 18 % of school students aged 15–16 
reported lifetime use of illicit drugs (Hibell et al., 2012). 
Furthermore, around 58 % of clients entering treatment 
started using drugs before the age of 20 (EMCDDA, 2012).
Thus, substance experimentation in adolescence increases 
the risk of persistent substance use and dependence 
(Bauman and Phongsavan, 1999; Brook et al., 1999; Gil et al., 
2004; Timberlake et al., 2007; Winters and Lee, 2008).
Early initiation into substance use appears also to be closely 
correlated with risky sexual behaviours, delinquency, chronic 
offending, depression, school failure and unemployment, 
troubled relationships with peers and family members, and 
low self-esteem throughout adolescence and adulthood (Guo 
et al., 2002; Stueve and O’Donnell, 2005). This is particularly 
true for high-risk subgroups such as runaways and the 
homeless, adolescents in drug treatment or suffering from 
mental disorders and those in the juvenile justice system 
(Malow et al., 2006; Rowe et al., 2010).
I Description of the intervention
Multidimensional family therapy (MDFT) is an integrative, 
family-based, multiple systems-oriented treatment specifically 
targeted at adolescents who use drugs and exhibit related 
behaviour problems (Liddle, 2002). The goal is to reduce 
symptoms and to enhance developmental functioning by 
facilitating changes in several behavioural domains. Therapists 
work simultaneously in four interdependent treatment 
domains depending on the particular risk and protection 
profile of the individual and his or her family: (1) the 
adolescent domain helps adolescents to engage in treatment, 
communicate with, and relate effectively to, their parents and 
other adults, and to develop social competence and 
alternative behaviours to drug use; (2) the parent domain 
engages parents in therapy, increases their behavioural and 
emotional involvement with their children and improves 
parental monitoring and limit-setting; (3) the family 
interactional domain focuses on reducing conflict and 
improving emotional attachments and patterns of 
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Family-based therapy appears to be effective in reducing not 
only drug use, but also problem behaviours associated with 
substance use such as delinquency and externalising and 
internalising symptoms. This is particularly relevant during 
adolescence, when substance misuse typically causes a 
constellation of problems (e.g. psychiatric symptoms, 
problems at school, delinquency, high-risk sexual behaviour). 
MDFT seems to be effective in adolescents of all backgrounds 
and ethnicity and can be delivered in a variety of routine care 
settings. Because adolescent substance users are found in 
numerous care settings (e.g. substance misuse treatment 
facilities, juvenile correction centres, mental health clinics, 
child welfare systems, schools), treatments that can be 
flexible will have great appeal to stakeholders and greater 
viability within and across sectors. MDFT is an example of 
family-based therapy that has been adapted and tested as an 
indicated preventative intervention for high-risk young people 
(Hogue et al., 2002, 2005), an early intervention for 
substance-using adolescents (Liddle et al., 2004), an 
outpatient treatment for adolescent drug misusers with 
co-occurring psychological problems (Liddle et al., 2001), an 
adjunctive family intervention integrated within a hospital-
based day-treatment programme (Liddle et al., 2002b, 2006b), 
and an intensive home-based intervention with case 
management for adolescents in the juvenile justice system 
who exhibit co-morbid substance use and conduct disorders 
(Liddle, 2002).
I How the intervention works
MDFT brings together the clinical and theoretical approaches 
of developmental psychology and psychopathology, the 
ecological perspective and family therapy. Adolescent 
developmental psychology and psychopathology research 
have determined that: (1) the greatest influence on healthy 
identity formation and development is the family; (2) family 
influence helps to buffer the effect of deviant peer culture; and 
(3) adolescents need to develop an interdependent rather 
than an emotionally separated relationship with their parents. 
A multidimensional perspective holds that symptom reduction 
and enhancement of prosocial and normative developmental 
functions in problem adolescents can be achieved by 
targeting the family as the focus of the intervention. MDFT 
views family functioning as instrumental in creating new, 
developmentally adaptive lifestyle alternatives for the 
adolescent.
MDFT seems also to improve treatment engagement and 
retention of high-risk adolescents (Jackson-Gilfort et al., 2001; 
Liddle et al., 2006a). Multiproblem families require an 
intensive approach that involves the young people, their 
caregivers and extrafamilial support systems (Cunningham 
and Henggeler, 1999). Retention rates (i.e. completion of a full 
course of prescribed treatment) in controlled trials of family-
based treatments have been uniformly high, typically from 
70 % to 90 % (Liddle et al., 2004). Clients who remain in 
treatment experience better outcomes.
Adolescent community reinforced approach (ACRA) is a 
behavioural intervention that aims to replace environmental 
factors that have supported substance use with activities 
and behaviours that support recovery.
Adolescent group therapy (AGT) is a group therapy model 
adapted to adolescents.
Cognitive behavioural therapy (CBT) is a psychotherapeutic 
treatment modality that can be offered in an individual or 
group format (Hofmann et al., 2013). It is empirically 
supported as a treatment for substance use disorders and 
has been shown to be effective in studies containing 
samples of primary cannabis users. Based on CBT’s 
effectiveness in adults with addictive behaviours, outpatient 
CBT is often considered a standard, first-line treatment for 
adults with substance use disorders, though less evidence 
is available for adolescents. In general, CBT interventions 
involve challenging irrational, negative thinking styles that 
are thought to promote negative affective states, which in 
turn promote maladaptive behaviours, such as problem 
cannabis use. In addition to helping patients to develop new 
ways of thinking, CBT interventions promote the 
development of alternative coping skills and the 
implementation of behavioural strategies for reducing and 
eliminating problem behaviours (e.g. substance abuse). 
When CBT is used in substance abuse/dependence 
treatment, it tends to focus on changing maladaptive 
behaviours and cognitions related to substance abuse by 
means of self-control training (e.g. stimulus control 
techniques), social and coping skills training and relapse 
prevention. CBT practitioners sometimes incorporate 
motivational elements into the earliest stages of therapy 
when working with individuals who have substance use 
disorders; however, these interventions are often derived 
from motivational interview (MI)/motivational enhancement 
Psychosocial approaches to treating drug-related problems in adolescents compared with  
MDFT in this review
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standard methodology for systematic reviews, the possibility 
that their results are biased cannot be excluded. A protocol for 
a Campbell Collaboration review on ‘Multidimensional Family 
Therapy (MDFT) for young people in treatment for non-opioid 
drug use’ was recently published (Rasmussen et al., 2012).
The overall goal of this review is to systematically appraise the 
evidence on the effectiveness of MDFT in treating illicit drug 
misuse in adolescents. More specifically, the aim is to assess 
the effectiveness of MDFT, compared with other therapies or a 
placebo, in treating young people who misuse illicit drugs, in 
retaining patients in treatment and in reducing illicit drug 
misuse.
I Methods
In order to select the studies for inclusion in this review, we set 
some criteria. We decided to search and include all the 
studies comparing MDFT with a control intervention for 
adolescent illicit drug misusers, provided they utilised an 
experimental design (e.g. RCTs and cluster RCTs).
I Why this review?
The effectiveness of available treatments for adolescent drug 
misusers is currently a reason for concern owing to the high 
rates of treatment drop-out and post-treatment relapse 
(Austin et al., 2005). Studies assessing the effectiveness of 
treatments for adolescent illicit drug users have not yet 
reached conclusive results (Austin et al., 2005; Littell et al., 
2005; Waldron and Turner, 2008; Williams and Chang, 2000). 
The evidence needed to make informed clinical decisions 
about the most effective interventions for adolescents who 
misuse substances is still uncertain.
Although family-based therapies represent a promising 
approach for the treatment of drug misuse, there is a need to 
determine what family-based interventions work, and for 
which types of families and adolescent drug users.
Recent overviews of research on family-based treatments for 
adolescent illicit drug users suggest that MDFT may be 
effective (Baldwin et al., 2012; Becker and Curry, 2008; Hogue 
and Liddle, 2009; Rowe et al., 2010; Vaughn and Howard, 
2004). However, as these studies do not conform to the 
treatment (MET) interventions, which will be discussed in 
more detail later. When CBT is used to treat problem 
cannabis use specifically, initial treatment sessions often 
involve developing skills directly related to achieving and 
maintaining abstinence (e.g. cannabis use self-monitoring, 
refusal and craving coping skills, increasing social support 
and non-drug-related activities, problem-solving training, 
coping with relapse). Later CBT sessions may focus on 
topics and skills indirectly related to maintaining abstinence 
(e.g. anger/frustration and anxiety/depression 
management, delinquent behaviour, impulse control, 
self-efficacy, effective communication).
Multidimensional family therapy (MDFT) (Liddle et al., 2001) 
is a family systems-oriented outpatient intervention for 
adolescents and young adults. It is empirically supported to 
be an effective treatment for cannabis use disorders. The 
intervention is designed to address problem cannabis use at 
four different levels: the adolescent; the adolescent’s 
parents; the adolescent’s family; and the adolescent’s 
extrafamilial network, which includes friends, peers and 
school, work or leisure settings. The fundamental principle 
underlying MDFT is that the family is instrumental in treating 
problem cannabis use by helping the adolescent to create 
new, developmentally adaptive lifestyle alternatives. Thus, 
interventions are aimed at improving family functioning, 
communication and accountability. MDFT was originally 
launched as a cannabis-specific treatment (CST) in five 
European countries (Belgium, Germany, France, the 
Netherlands, and Switzerland) as part of the INCANT study 
(Rigter et al., 2010). The goal of the randomised controlled 
trial (RCT) was to introduce an evidence-based cannabis 
use treatment targeting adolescents in European countries. 
Currently, MDFT is the most widely offered systems-based 
CST programme in Europe.
Multifamily education intervention (MEI) consists of 
interventions used in mental health to inform and support 
patients’ relatives.
Motivational enhancement therapy (MET) is a therapy for 
substance-use disorders that relies heavily upon the 
principles of MI.
Motivational interviewing (MI) is a client-centred, semi-
directive method for enhancing intrinsic motivation to 
change by exploring and resolving ambivalence (Smedslund 
et al., 2011).
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potentially relevant studies. Concluding, on-going or 
unpublished studies were identified by searching the Internet 
and contacting authors. For example, the website of the 
developers of MDFT was searched.
I Data collection and analysis
Two authors independently screened 107 titles and 
abstracts identified through the search strategies. When the 
abstracts suggested that the paper might be potentially 
relevant, the full text was read and the study was excluded if 
the focus was not on illicit drug use, if participants in the 
study were not illicit drug users seeking treatment and/or if 
the experimental intervention was not MDFT. Studies that 
were not RCTs were also excluded.
The assessment of the internal quality of the included studies 
was carried out by two independent reviewers using the 
Cochrane Collaboration’s tool for assessing the risk of bias 
(Higgins and Green, 2011). Disagreements arising during 
either screening or quality assessment were resolved through 
discussion.
Authors of the selected studies were contacted by email, in 
accordance with the procedure suggested by the Cochrane 
Collaboration, and asked to provide supplementary 
information so that this could be included in the analysis and 
in order to gain related published or unpublished references or 
papers.
I Results
I Included studies
We included five studies, which were described in 22 
publications (see References ‘Studies included in this review’), 
and we excluded three studies which initially seemed to be 
eligible. A detailed description of the included studies can be 
found in Annex 1. The table includes an assessment of the risk 
of the studies giving distorted results because of 
methodological inaccuracies (the so-called ‘risks of bias’).
I Study design and location
All five included studies were RCTs (in which the individual 
adolescent was randomly allocated to receive MDFT or a 
different intervention). Three trials were conducted at a single 
site (Liddle et al., 2001; Liddle et al., 2004; Liddle et al., 2008) 
and two were multisite studies (Dennis et al., 2004; Rigter et 
al., 2013). Four of the five studies were conducted in the 
In terms of participants, the studies were included if they 
involved adolescents (aged 11–18 years) reporting misuse (1) 
of illicit drugs and seeking treatment. Here the term 
‘adolescence’ refers to both early (11–13 years of age) and 
middle (14–18 years of age) adolescence as currently 
classified by the American Academy of Child and Adolescent 
Psychiatry. The term ‘misuse’ refers to regular excessive 
consumption of and/or dependence on illegal psychoactive 
substances as defined by each of the studies included. 
Studies targeting special populations (e.g. drug-misusing 
incarcerated adolescents, drug-misusing adolescent 
offenders, drug-misusing adolescents with co-morbid 
psychiatric disorders) were excluded.
The intervention studied was MDFT as a standalone 
intervention compared with alternative treatments, no 
intervention or standard treatment; for example, interventions 
aimed at primary prevention were excluded.
The primary outcomes of interest were any measure of illicit 
drug use in the last week, month or year and frequency of 
consumption, either self-reported or otherwise. Secondary 
outcomes included any direct or indirect self-reported 
measures of retention in treatment, drug-related problems, 
antisocial behaviours, poor school performance and alcohol 
misuse.
The studies were excluded if they did not focus on illicit drugs, 
if participants did not seek treatment or if they were not 
adolescents, if the experimental intervention was not or not 
only MDFT and if the study design was not experimental.
I Search strategy
In order to identify all the studies falling within our inclusion 
criteria, we performed structured web-based searches using a 
combination of relevant keywords. These search strategies 
were adapted to query the different specialised databases 
available, namely: the Cochrane Central Register of Controlled 
Trials (CENTRAL), an inventory of studies included in the 
systematic reviews of evidence; PubMed, the platform of the 
American National Library of Medicine, also called MEDLINE; 
and PsycINFO, a database grouping several American 
databases. The full search strategy for MEDLINE is available in 
Annex 4. We accepted references in all languages and to all 
publication statuses (i.e. studies published in scientific 
journals, dissertations and reports and unpublished studies 
were all given equal consideration when being assessed). We 
also inspected the reference lists of topic-related reviews and 
included and excluded studies in order to identify other 
(1)  There are often cultural and social differences in the definitions of the terms 
‘abuse’, ‘use’ and ‘misuse’. The aim of this review was not limited by imposing 
an arbitrary distinction between these terms. We relied upon the definitions 
provided in each identified study.
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I Interventions and comparisons (2)
All the studies compared MDFT with another intervention. The 
European study, for example, compared MDFT with individual 
psychotherapy (Rigter et al., 2013). The implementation of 
individual psychotherapy varied between sites, but always 
included motivational interviewing and CBT in addition to 
individual substance misuse counselling. The first of the 
studies, conducted in 2001 (Liddle et al., 2001), compared 
MDFT with AGT and MEI in community clinical settings.
In fact, both MDFT and MEI are family-based interventions, 
but MDFT is applied within an individual family whereas MEI is 
provided to several families at once. MEI is more structured 
and more psycho-educationally focused than MDFT. AGT uses 
an adolescent peer group format and focuses on the 
individual adolescent and his or her psychosocial 
development. In another study (Liddle et al., 2008), MDFT was 
compared with individual CBT in office-based outpatient 
settings. CBT is an intensive intervention that focuses on 
increasing coping competence and training skills. It adopts a 
modular approach whereby the therapist selects treatment 
strategies based on the individual adolescent’s needs.
MDFT was also compared with peer group therapy (Liddle et 
al., 2004), in which education was combined with skills 
training and social support. Four to six adolescents 
participated in each group, and each session was led by one 
therapist. The CYT study (Dennis et al., 2002) compared 
MDFT with five sessions of MET/CBT (MET/CBT5) and with 
the adolescent community reinforcement approach (ACRA) at 
two different sites. MET/CBT5 was the briefest individual and 
group approach, without any family involvement, while ACRA 
was primarily provided on an individual basis to the 
adolescent with some parent-only and family sessions. The 
number and duration of MDFT sessions provided was similar 
in all intervention groups in four trials (Liddle et al., 2001; 
Liddle et al., 2004; Liddle et al., 2008; Rigter et al., 2013), and 
service delivery was also identical in these studies. The 
majority of the MDFT sessions were conducted in the home, 
while the peer group therapy was conducted mainly at clinic 
offices. In the CYT study, each condition focused on different 
modalities of service, hours of contact, lengths of stay and 
numbers of days of contact. MET/CBT5 consisted of two 
individual MET sessions and three group CBT sessions with 
the total duration of treatment being 6–7 weeks. ACRA 
comprises 10 individual sessions with the adolescent and four 
sessions with caregivers (two with the whole family) over a 
period of 12–14 weeks. MDFT is delivered in 12–15 sessions 
over a period of 12–14 weeks. In the INCANT study, MDFT and 
individual psychotherapy did not differ in session duration.
(2) The characteristics of intervention treatment are reported in Annex 2.
United States of America (Dennis et al., 2004; Liddle et al., 
2001; Liddle et al., 2004; Liddle et al., 2008) and one in 
Europe (Rigter et al., 2013).
I Participants
The total number of adolescents who participated in the five 
studies was 1 539, and numbers ranged from 83 (Liddle et al., 
2004) to 450 (Rigter et al., 2013) per study. The study 
participants’ mean age at baseline ranged from 13.7 years 
(Liddle et al., 2004) to 16.3 years (Rigter et al., 2013). In one of 
the studies, the age of participants was not reported. In all the 
studies, more boys than girls were included (from 74 % (Liddle 
et al., 2004) to 86 % (Rigter et al., 2013)). In terms of ethnicity, 
the participants in the studies conducted in the USA were 
predominantly white/Caucasian, African American or Hispanic 
(Liddle et al., 2001; Liddle et al., 2004; Liddle et al., 2008; 
Dennis et al., 2004). In one study, the majority of participants 
were African American (72 %) (Liddle et al., 2008). In two 
studies, the participants were mainly white/Caucasian 
(Dennis et al., 2004; Liddle et al., 2001), with 61 % and 51 % 
respectively. One study (Liddle et al., 2001) included Asian 
participants and in another (Liddle et al., 2004) 42 % of 
participants were Hispanic and Haitian/Jamaican. Information 
on ethnic composition was not reported for the European 
study (Rigter et al., 2013), but it was specified that 40 % of 
participants were of first- or second-generation foreign 
descent. In all included studies, participants were drug users 
at the start of treatment (Dennis et al., 2004; Liddle et al., 
2001; Liddle et al., 2004; Liddle et al., 2008; Rigter et al., 
2013). In one of the studies (Liddle et al., 2001), 51 % of 
participants were polydrug users while the remainder (49 %) 
used only marijuana and alcohol. Furthermore, in one of the 
studies by Liddle et al. (2008), 75 % of participants met 
criteria for cannabis dependence, 20 % the criteria for alcohol 
dependence and 13 % the criteria for other drug dependence; 
13 %, 4 % and 2 %, met the criteria for cannabis, alcohol and 
other drug misuse, respectively. Criteria for general substance 
misuse and substance dependence were present in, 
respectively, 47 % and 16 % of patients in another study 
(Liddle et al., 2004).
In another study (Dennis et al., 2004), most participants 
(75 %) used at least one substance (alcohol included) weekly 
or daily and 71 % used cannabis weekly or daily. In the INCANT 
study (Rigter et al., 2013), 84 % of all participants qualified as 
cannabis dependent, with the remaining 16 % being cannabis 
users.
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In the first of the studies (Liddle et al., 2001), the investigators 
interviewed the adolescents and their parents separately and 
asked about the participants’ frequency of drug use over the 
previous 30 days. Information collected from the interviews 
and urine analyses reports were reviewed by three 
experienced clinicians, who rated the severity of drug use. 
Some of the studies used validated checklists to measure the 
severity of substance use, such as the Personal Involvement 
with Chemicals (PIC) scale and the Personal Experience 
Inventory (PEI), a multi–scale self-report measure assessing 
the severity of a substance use problem and the psychological 
risks. In another study, adolescents’ substance use was 
measured with the Timeline Follow-back (TLFB) method and 
the Problem Oriented Screening Instrument for Teenagers 
(POSIT) Substance Use and Abuse subscale. The TLFB 
method was used to determine substance use frequency. In 
this method, a calendar and other memory prompts are used 
to stimulate recall of previous substance use. Participants 
retrospectively report use of specific substances on each day 
over the 30-day period prior to each assessment. The total 
drug use score is the number of days in the previous 30 days 
on which participants have used any drug. POSIT is a self-
report multi-problem screening instrument designed to screen 
for substance use and other problems.
Another measure used was the Global Appraisal of Individual 
Needs (GAIN), a standardised clinical assessment with eight 
main sections (including substance use). The GAIN was 
supplemented with additional measures including the 
Adolescent Reasons for Quitting (ARFQ) Questionnaire 
adopted from the Marijuana Treatment Project and a similar 
instrument dealing with tobacco use. Parents were asked to 
complete the Collateral Assessment Form (CAF), an 
assessment battery including questions about symptoms of 
substance use disorders and frequency of using cannabis, 
alcohol and other drugs.
In the European study, cannabis use disorder was assessed 
with the Adolescent Diagnostic Interview-Light (ADI-Light for 
cannabis), a brief, structured interview based on the criteria of 
the Diagnostic and Statistical Manual of Mental Disorders 
(4th edition) for substance use disorders in adolescence. The 
frequency of the adolescents’ cannabis use was measured 
using the TLFB method.
I Detailed comparisons
In total, five comparisons were made, as follows:
–  MDFT versus family therapy: one study (Liddle et al., 2001)
–  MDFT versus individual therapy: two studies (Liddle et al., 2008; 
Rigter et al., 2013)
–  MDFT versus group therapy: two studies (Liddle et al., 2001; Liddle 
et al., 2004)
–  MDFT versus a combination of individual and group therapy: one 
study (Dennis et al., 2004)
–  MDFT versus a combination of individual and family therapy: one 
study (Dennis et al., 2004)
Around 11 different outcomes were measured in the studies. 
Four studies measured whether MDFT reduced general drug 
use; three studies measured the severity of general drug use/
problem drug use.
The European study measured the prevalence of cannabis use 
disorder, whereas frequency of general drug use was 
measured in three studies (Liddle et al., 2004; Liddle et al., 
2008; Dennis et al., 2004) and four studies measured the 
frequency of cannabis use (Dennis et al., 2004; Liddle et al., 
2004; Liddle et al., 2008; Rigter et al., 2013). Three of these 
also measured the frequency of alcohol use (Dennis et al., 
2004; Liddle et al., 2004; Liddle et al., 2008) and two 
measured the frequency of other drug use (Dennis et al., 
2004; Liddle et al., 2008). Beyond drug use, three studies 
measured problem behaviours (Dennis et al., 2004; Liddle et 
al., 2001; Liddle et al., 2004) and two the school experience 
(Liddle et al., 2001; Liddle et al., 2004). Family functioning was 
measured in four studies (Dennis et al., 2004; Liddle et al., 
2001; Liddle et al., 2004; Liddle et al., 2008).
Psychological well-being and possible psychiatric or 
personality disorders were measured in three studies (Dennis 
et al., 2004; Liddle et al., 2004; Liddle et al., 2008).
In three studies (Dennis et al., 2004; Liddle et al., 2001; Liddle 
et al., 2004), information on each adolescent was obtained 
from multiple sources, comparing self-reporting with parents’ 
reports and, in one case, with urine tests to check for 
substance use.
TABLE 1
Periodicity of assessment with the adolescents
Study
Treatment 
conclusion
3 months 6 months 9 months 12 months
Liddle et al. (2001) • • •
Liddle et al. (2004) • • •
Dennis et al. (2004) • • • • •
Liddle et al. (2008) • • •
Rigter et al. (2013) • • • •
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In four studies (Dennis et al., 2004; Liddle et al., 2004; Liddle 
et al., 2008; Rigter et al., 2013), the instruments used for 
measuring drug use were validated (or their psychometric 
properties reported).
The instruments administered were self-report questionnaires 
in three trials (Liddle et al., 2004; Liddle et al., 2008; Rigter et 
al., 2013) and structured interviews in two trials (Dennis et al., 
2004; Liddle et al., 2001). In some of the studies, the 
adolescents were interviewed in order to measure all of the 
aforementioned dimensions three months after initiating the 
study. In others, they were interviewed up to 12 months later. 
In particular, four studies assessed the participants at the end 
of the treatment period, two studies assessed the participants 
after three months from treatment completion, five studies 
after six months, two studies after nine months and five 
studies after 12 months (see Table 1).
Meta-analysis was not possible owing to the heterogeneity in 
the methods applied to measuring drug use. The main results 
are shown in Annex 1 and presented here in the form of a 
narrative systematic review.
I Effects on drug use and abstinence
Reduction in drug use (including alcohol, marijuana and 
other drugs)
MDFT versus AGT
In one study (Liddle et al., 2001), MDFT was compared with 
AGT. After 12 months, both groups showed a reduction in drug 
use (including alcohol, marijuana and other drugs) but the 
MDFT groups obtained better, though not statistically significant, 
results.
MDFT versus MEI
The same study also compared MDFT with MEI finding similar 
results. After 12 months, both groups showed a reduction in 
drug use (including alcohol, marijuana and other drugs), which 
was greater in the MDFT group (–57 %) than in the MEI group 
(–27.6 %). The results were considered statistically significant.
MDFT versus CBT
Another study (Liddle et al., 2008) compared MDFT with CBT. 
In a 12-month assessment, in both groups the adolescents 
reported having reduced their cannabis use in the last 30 
days, with the adolescents in the MDFT group reporting a 
higher reduction than the comparison group; however, the 
results were not considered statistically significant. During the 
same assessment, these adolescents also reported that their 
use of drugs (other than cannabis and alcohol) was reduced in 
the MDFT group (–91 %) but increased in the CBT group 
(+92 %), and the result was statistically significant. 
Furthermore, the proportion of young people reporting 
minimal substance use (no use of alcohol or drugs or use on 
only one occasion) at the 12-month evaluation was 
significantly higher in the MDFT group (64 %) than in the CBT 
group (44 %). The authors of the study wanted to check 
whether the effect of MDFT and CBT on substance use 
frequency differed according to drug use severity, but they did 
not find statistically significant differences between 
treatments in either the high-severity, or low-severity groups.
TABLE 2
Summary of main results
Study
Multidimensional  
Family Therapy
Comparison Reference
Use of cannabis and other drugs
MDFT versus group therapy (AGT, peer group therapy) ++ + Liddle et al. (2001)
MDFT versus family therapy (MEI) ++ + Liddle et al. (2001)
MDFT versus individual therapy (CBT) ++ + Liddle et al. (2004)
MDFT versus group therapy ++ + Liddle et al. (2004)
MDFT versus a combination of individual and group therapy  
(MET and CBT-5 sessions)
++ +* Dennis et al. (2004)
MDFT versus a combination of individual and family therapy (ACRA) + ++ Dennis et al. (2002)
MDFT versus individual psychotherapy (INCANT individual sessions) ++ + Rigter et al. (2013)
Effects on severity of drug use
MDFT versus individual therapy (CBT) ++ + Liddle et al. (2008)
MDFT versus peer group therapy ++ + Liddle et al. (2004)
++ improvement in the outcomes in comparison with baseline and control group
+ improvement in the outcomes in comparison with baseline only
* the difference of the two groups was not statistically significant
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psychotherapy group). Nevertheless, both treatments reduced 
the number of cannabis consumption days across 
assessments. The frequency of cannabis consumption fell 
more in the high-severity MDFT group than in the individual 
psychotherapy group.
Effects on severity of drug use
MDFT versus CBT
In the study which compared MDFT with CBT (Liddle et al., 
2008), the reduction in the severity of drug use problems was 
greater in the MDFT group (–59 %) than in the CBT group 
(–29 %). In both groups, this change from the beginning of the 
treatment was statistically significant. Nevertheless, the 
reduction in substance use problem severity was significantly 
greater in the MDFT group than in the CBT group after the 
six-month assessment and 12-month follow-up, but not at 
intake or at treatment completion.
The authors conducted an analysis in the group with the lower 
severity drug use and did not find differences among the two 
comparison groups, whereas in the higher severity subgroup, 
there were statistically significant differences in treatment 
effects in favour of MDFT.
MDFT versus peer group therapy
The study comparing MDFT with peer group therapy (Liddle et 
al., 2004) found an equally distributed reduction in the 
number of substance-related problems at the 12-month 
follow-up in both the MDFT group and the peer group therapy 
group (–79 % and –27 %, respectively), with the reduction 
being significantly higher in the MDFT group. The drop in the 
number of participants reporting any substance use problems 
was greater in the MDFT group (–65 %) than in the peer group 
therapy group (–32 %), but the difference between the groups 
was not statistically significant.
I Discussion
The aim of this systematic review was to evaluate the 
effectiveness of MDFT. The inclusion criteria led to five RCTs 
being considered for analysis: four from the USA and one from 
Europe. All of the studies showed that MDFT and the other 
treatments considered led to a reduction in substance use.
The studies provide some evidence that MDFT is more 
effective in reducing drug use (alcohol, marijuana and other 
drugs) than either MEI or peer group therapy, and more 
Alcohol use measured after 12 months was lower in the CBT 
group (–18 %) than in the MDFT group (+15 %) but the 
difference between the treatment groups was not significant.
MDFT versus peer group therapy
A further study (Liddle et al., 2004) compared MDFT with peer 
group therapy. After 12 months, the adolescents in the MDFT 
group reported a higher reduction in 30-day frequency of 
substance use (alcohol and drugs) than those in peer group 
therapy (–85 % and –28 %, respectively), and the difference 
between the groups was statistically significant. In addition, in 
both groups the adolescents reported a reduction in the use 
of any drugs (–72 % and –26 %, respectively); the probability 
of being abstinent was much higher for those in the MDFT 
group {2.20 [95 % confidence interval (CI) = 0.77–6.33]}. 
Furthermore, more adolescents completed the treatment in 
the MDFT group (97 %) than in the peer group therapy (72 %), 
and the result was statistically significant.
MDFT versus MET and CBT (5 sessions)
One study (Dennis et al., 2004) compared MDFT with MET/
CBT5 and found a slightly higher number of days abstinent 
from cannabis use during 12 months among the adolescents 
of the MDFT group (257) than in the MET/CBT5 group (251), 
however the difference was not statistically significant.
MDFT versus ACRA
One study (Dennis et al., 2004) compared MDFT with ACRA 
and found that the mean total number of days abstinent from 
cannabis use over the 12-month follow-up period was slightly 
lower in the MDFT group.
MDFT versus individual psychotherapy
The European study (INCANT) compared MDFT with 
individual psychotherapy. At the 12-month assessment, a 
lower percentage of adolescents in the MDFT group reported 
dependence on cannabis (38 % vs. 52 % in the individual 
therapy group). Abuse of cannabis was reported by 33 % of 
adolescents in the MDFT group and 22 % in the individual 
psychotherapy group, and a higher percentage of adolescents 
no longer experienced cannabis use disorder in the MDFT 
group than in the individual psychotherapy group (18 % and 
15 %, respectively). MDFT also obtained better results in 
terms of the number of dependence symptoms during the 12 
months from the beginning of the treatment and mean 
number of consumption days (these were reduced by 43 % 
(35 days) in the MDFT group and by 31 % in the individual 
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individual, group, family), orientation (e.g. cognitive, 
behavioural, educational, family system) and dose (sessions 
and intensity). Compared with other treatments, MDFT is 
characterised by its longer duration and higher intensity; the 
higher treatment dose could explain the added benefits of 
MDFT compared with less intense treatments and treatments 
of shorter duration (e.g. CBT).
The quality of included studies was generally acceptable: they 
were all randomised trials, and most of them incorporated 
some element of concealment or blinding, even though these 
are not common characteristics of behavioural interventions. 
However, although the populations under study were larger 
than in many pharmacological trials, it was not possible to 
conduct a meta-analysis because of the considerable 
variability in outcomes across studies, the lack of numerical 
information — such as absolute numbers — in many 
publications and, in particular, the variability in comparison 
treatments (MEI, AGT, CBT, and so on), all of which prevent 
any pooling of data.
In conclusion, our results support the use of MDFT as a 
treatment for established substance misuse and related 
problems in young people, even if its superiority to all possible 
alternatives has not been established. The advantages of 
MDFT are its capacity to reduce substance abuse problems, 
the low drop-out rate and the long duration of effects. A 
possible explanation of these effects is that MDFT is delivered 
at higher intensity than other treatments, suggesting the need 
for an accurate cost–benefit analysis.
I Implications for practice
MDFT can be adopted in practice for the treatment of 
adolescent illicit drug use, provided local resources can 
implement such an intensive programme.
As intervention techniques are linked to positive outcomes in 
adolescents (Hogue et al., 2006, 2008a), it is necessary for 
professionals to guarantee implementation fidelity. To this 
end, the creators of MDFT have also developed the Therapist 
Behaviour Rating Scale (TBRS) — an observational measure 
of adherence and competence in family-based therapy for 
adolescent substance abuse (Hogue et al., 2008b), which is 
recommended as a tool for practice.
Since effectiveness requires all members of the families 
concerned to engage with the treatment, adherence is another 
critical issue to be considered in implementation, and this may 
be an obstacle when offering this intervention to more 
problematic adolescents (i.e. those whose families are not 
available to take part in the therapy).
effective than individual psychotherapy in reducing the risk of 
cannabis dependence. Compared with CBT, MDFT appears to 
be more effective in reducing drug problem severity and use 
of other drugs (i.e. drugs other than cannabis and alcohol), but 
not in reducing cannabis use or promoting minimal substance 
use (use of alcohol or drugs on zero or one occasions). On the 
other hand, MDFT appears to be equivalent to AGT in reducing 
drug use (alcohol, marijuana and other drugs) and to ACRA 
and MET/CBT5 in increasing the number of days abstinent 
from cannabis use. As for secondary outcomes, it appears 
that MDFT reduces substance use-related problems more 
than peer group therapy and decreases drug use problem 
severity more than CBT.
MDFT therefore seems to be an effective treatment option for 
adolescent cannabis users. MDFT also appears to be more 
effective in decreasing the number of cannabis consumption 
days compared with individual psychotherapy and in reducing 
drug use problem severity compared with CBT in subgroups 
of high-risk adolescents. Thus, MDFT could be indicated for 
adolescents who are heavy cannabis users or who have a 
severe drug use disorder.
The effects of MDFT seem to persist over time and, in most 
cases, the results at the 12-month follow-up are better than 
those observed at the previous follow-ups. Positive outcomes 
at discharge and in the period immediately following 
treatment end are maintained among MDFT-treated 
adolescents over time.
These results appear to be sustained by recent meta-analyses 
suggesting that family therapy has a modest added benefit 
beyond treatment in comparison with usual and alternative 
treatments (Baldwin et al., 2012; Waldron and Turner, 2008).
Another result of the review is that MDFT appears to be more 
acceptable to clients than other treatments, as the 
adolescents tend to remain in treatment until its completion.
Moreover, several studies have shown that treatment 
engagement and successful outcomes can be more difficult to 
achieve in adolescents who have co-occurring substance use 
and problem behaviours (Cornelius et al., 2003; Grella et al., 
2001; Rowe et al., 2004).
The level of engagement and follow-up rates in the MDFT 
arms of the studies included were good, as was intervention 
fidelity. The treatments were reasonably acceptable to the 
adolescents and their families, as evidenced by reported 
participation and retention rates.
MDFT has been tested against distinct alternatives for 
adolescent substance misuse in terms of modality (e.g. 
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I Conclusions
The present review is based on five studies, four of which were 
carried out by the same investigators in the USA across seven 
years, the fifth being a multisite study conducted in Europe. 
Further studies may be needed to confirm the preliminary 
positive results presented in this paper.
Two specific questions must be addressed: which profile of 
adolescent substance misusers is most likely to benefit from 
MDFT, and what is its cost–benefit balance compared with 
other alternatives?
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I Annexes
Abbreviations used in the annexes
ACRA adolescent community reinforcement approach
AGT adolescent group therapy
CBT cognitive–behavioural therapy
CI confidence interval
CYT Cannabis Youth Treatment
DSM-IV Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition
FSN family support network
FU follow-up
HS high severity
IP individual psychotherapy
ITT intention to treat
LS low severity
MDFT multidimensional family therapy
MEI multifamily educational intervention
MET/CBT5 five sessions of motivational enhancement 
treatment with CBT
MET/CBT12 12 sessions of MET and CBT
NR not recorded
NS not significant
OR odds ratio
RCT randomised controlled trial
SD standard deviation
SE standard error
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I Annex 1
Characteristics of included studies
Study 1 (Liddle et al., 2001) Study 2 (Liddle et al., 2008) Study 3 (Liddle et al., 2004) Study 4 (CYT) Study 5 (INCANT)
Methods
Design RCT RCT RCT RCT Multicentre RCT with an open-label, 
parallel-group design
Follow-up 6 and 12 months after treatment 
termination
6 and 12 months after treatment 
termination
6 and 12 months after treatment 
intake
3, 6, 9 and 12 months 3, 6, 9 and 12 months after 
treatment termination
Attrition 16 % 22 % 36 % 15 % NR
Intention to treat NR Yes Yes Yes Yes
Unit of randomisation Individual adolescent Individual adolescent Individual adolescent Individual adolescent Individual adolescent
Participants
Number of individuals randomised:
Intervention NR NR NR NR NR
Control Control 1: NR
Control 2: NR
NR NR NR NR
Total NR 287 130 702 721
Number of individuals participating:
Intervention NR 112 40 100 (MDFT) 212
Control Control 1: NR
Control 2: NR
112 43 Control 1 (MET/CBT5): 102
Control 2 (MET/CBT12): 96
Control 3 (FSN): 102
Control 4 (MET/CBT5): 100
Control 5 (ACRA): 100
238
Total 182 224 83 600 450
Number of individuals analysed:
Intervention 47 112 40 100 (MDFT) 212
Control Control 1: 53
Control 2: 52
112 43 Control 1 (MET/CBT5): 102
Control 2 (MET/CBT12): 96
Control 3 (FSN): 102
Control 4 (MET/CBT5):100
Control 5 (ACRA): 100
238
Total 152 224 83 600 450
Age (in years) Mean 15.9 (SD 1.4), range 13–18 Mean 15.4 (SD 1.23), range 12–17.5 Mean 13.73 (SD 1.1), range NR 13–14: 15 %; 15–16: 55 %; 17–18: 
30 %
Mean 16.3 (SD 1.2), range 13–18
Sex (male) 80 % 81 % 74 % 83 % 85 %
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Study 1 (Liddle et al., 2001) Study 2 (Liddle et al., 2008) Study 3 (Liddle et al., 2004) Study 4 (CYT) Study 5 (INCANT)
Ethnicity Hispanic: 15 %; African American: 
18 %; Asian: 6 %; white non-
Hispanic: 51 %; other: 10 %
Hispanic: 10 %; African American: 
72 %; white non-Hispanic: 18 %
Hispanic: 42 %; African American: 
38 %; Haitian or Jamaican: 11 %; 
white non-Hispanic: 3 %
White: 61 %, African American: 30 %; 
Hispanic: 4 %
NR (40 % were of first- or second-
generation foreign descent)
Country USA USA USA USA Belgium, Germany, France, 
Netherlands, Switzerland
Illicit drug use Polydrug users: 51 %; strictly 
marijuana and alcohol users: 49 %
75 % met DSM-IV criteria for 
cannabis dependence and 13 % for 
other drug dependence; 13 % met 
DSM-IV criteria for cannabis abuse 
and 2 % for other drug abuse
47 % met criteria for substance use; 
16 % met criteria for substance 
dependence
86 % met criteria for a cannabis-
related disorder; 12 % reported 
substance use disorders
Dependent on cannabis: 84 %
Interventions
Type MDFT MDFT MDFT MDFT MDFT
Treatment retention 30 % did not complete MDFT, 35 % 
dropped out of MEI, 47 % dropped 
out of AGT. The percentage of 
participants completing treatment 
was higher in the MDFT condition 
than in the AGT condition (70 % vs. 
53 %, p = 0.03). Treatment retention 
rates between the two family-based 
treatments — MDFT (70 %) and MEI 
(65 %) — were not significantly 
different
– – – –
Fidelity NR 90 % of participants in each 
condition successfully completed 
therapy
97 % of young people in MDFT 
completed treatment compared 
with 72 % in AGT.
None of the MDFT participants, 
compared with 7 % of the peer 
group therapy participants, failed to 
attend at least one treatment 
session. The percentage of 
participants completing treatment 
was higher in the MDFT condition 
than in the AGT condition (97 % vs. 
72 %, p < 0.05)
71 % completed treatment NR
Duration/frequency Each of the three treatments 
consisted of a minimum of 14 and a 
maximum of 16 weekly sessions, 
which covered a period of 5–6 
months in a clinic setting. Treatment 
dosage and duration were equalised 
across the three intervention groups
MDFT and CBT were delivered in 
60- to 90-minute weekly sessions. 
Both treatments were designed to 
be 4–6 months in duration
Both treatments were conducted 
twice a week (90-minute sessions) 
for 12–16 weeks
12–14 weeks 5–7 months
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Study 1 (Liddle et al., 2001) Study 2 (Liddle et al., 2008) Study 3 (Liddle et al., 2004) Study 4 (CYT) Study 5 (INCANT)
Control Control 1: AGT
Control 2: MEI
MDFT was compared with two 
manualised active treatments, AGT 
and MEI, with 182 clinically referred 
marijuana- and alcohol-abusing 
adolescents. All treatments 
consisted of 14–16 90-minute 
sessions conducted over 5–6 
months in an outpatient office or 
clinic. MDFT used a family 
therapeutic approach with individual 
families, while MEI served groups of 
three or four families in a more 
structured and psycho-educational 
setting. AGT consisted of groups of 
six to eight adolescents led by two 
therapists and emphasised the 
development of social skills, 
self-control, self-acceptance and 
problem-solving skills
Individual CBT
MDFT was compared with an 
empirically supported individual-
based adolescent treatment (CBT) 
with 224 primarily male and African 
American adolescents referred to a 
drug treatment clinic. Adolescents 
who met DSM-IV criteria for 
cannabis, alcohol and/or other drug 
dependence were assigned to one 
of two manual-based treatment 
conditions — MDFT or CBT — 
consisting of 60- to 90-minute 
sessions conducted weekly in an 
outpatient office setting. 
Adolescents in the CBT condition 
received individual therapy, although 
parents attended the first two 
treatment sessions. CBT sessions 
first aimed to prioritise problems and 
construct a treatment ‘contract’ and 
then focused on information/
education and providing problem-
solving skills training
AGT
MDFT was tested as an early 
intervention for 83 young minority 
adolescents referred for drug 
treatment in Miami
Control 1: MET/CBT5
Control 2: MET/CBT12
Control 3: FSN
Control 4: ACRA
In two trials of a randomised 
controlled study (CYT), five 
manual-driven treatment 
interventions for adolescents with 
cannabis-related disorders were 
compared across four sites. Trial 1 
compared the following 
interventions at two sites: MET/
CBT5; MET/CBT12; FSN
Trial 2 compared the following 
interventions at two sites: MDFT; 
ACRA; MET/CBT5
IP 
Outcomes Drug use from intake to 12-month 
follow-up (FU) —mean (SD)
MDFT
Intake: 9.89 (3.79) 
Termination: 4.79 (3.20) 
6-month FU: 5.04 (3.77) 
12-month FU: 4.25 (2.98)
AGT
Intake: 8.83 (2.76) 
Termination: 7.33 (3.41)
6-month FU: 6.21 (3.66) 
12-month FU: 5.08 (3.71)
MEI
Intake: 10.03 (3.45) 
Termination: 7.26 (5.05) 
6-month FU: 6.87 (3.79) 
12-month FU: 7.26 (3.97)
Drug use problem severity —  
mean (SD)
MDFT
Intake: 28.47 (17.36) 
Termination: 19.75 (18.18) 
6-month FU: 18.88 (17.86) 
12-month FU: 11.66 (17.67)
CBT
Intake: 27.41 (15.65)
Termination: 27.39 (19.71)
6-month FU: 20.35 (18.73)
12-month FU: 19.43 (20.30)
Both treatments showed 
statistically significant decreases. 
The greater decrease was 
associated with MDFT [6-month FU 
(t = 2.12, p < 0.05, d = 0.039), 
12-month FU (t = 2.32, p < 0.05, 
d = 0.59)]
Substance use problems —  
mean (SD)
MDFT
Intake: 0.63 (0.78)
6-week FU: 0.13 (0.37)
Termination: 0.11 (0.28)
6-month FU: 0.08 (0.25)
12-month FU: 0.13 (0.30)
Peer group
Intake: 0.64 (0.71)
6-week FU: 0.37 (0.52)
Termination: 0.37 (0.69)
6-month FU: 0.44 (0.70)
12-month FU: 0.47 (0.72)
Significant reductions in both 
treatments in the number of 
substance-related problems over 
the 12-month FU (b = –0.24, 
pseudo-z = –8.35, p < 0.001). 
Significant treatment effect with 
greater reduction in MDFT 
(b = –0.14, pseudo-z = –10.47, 
p < 0.001, 95 % CI –0.16 to –0.11)
Total days of abstinence over 12 
months was not significantly 
different by site or condition (within 
and across sites):  
MET/CBT5 = 251
ACRA = 265
MDFT = 257
Effect size = 0.06 (ns)
Prevalence of cannabis 
dependence diagnosis — n (%)
Belgium
MDFT
Baseline: 29/30 (97 %)  
12-month FU: 13/30 (43 %)
Difference: 54 %
IP
Baseline: 28/30 (93 %)
12-month FU: 12/30 (40 %)
Difference: 40 %
France
MDFT
Baseline: 29/38 (76 %)
12-month FU: 13/38 (34 %)
Difference: 42 %
IP
Baseline: 46/63 (73 %)
12-month FU: 24/63 (38 %)
Difference: 35 %
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Study 1 (Liddle et al., 2001) Study 2 (Liddle et al., 2008) Study 3 (Liddle et al., 2004) Study 4 (CYT) Study 5 (INCANT)
Outcomes Changes across time from intake to 
termination to the FU periods for all 
subjects were significant (F = 31.45, 
p = 000). The interaction of time × 
treatment was also significant 
(F = 2.68, p = 0.05). At 12 months 
MDFT was not significantly different 
from MEI (t = –3.59, p = 0.0006) and 
AGT was significantly different from 
MEI (t = –2.36, p = 0.02).
Problem behaviour from intake to 
12-month FU — mean (SD)
MDFT
Intake: 83.34 (20.62) 
Termination: 71.87 (17.59) 
6-month FU: 67.22 (17.15) 
12-month FU: 63.56 (20.14)
AGT
Intake: 75.80 (26.61) 
Termination: 72.68 (26.02) 
6-month FU: 66.36 (21.11) 
12-month FU: 61.80 (16.92)
MEI
Intake: 83.42 (24.09)
Termination: 77.45 (22.93) 
6-month FU: 75.51 (24.29)
12-month FU: 71.57 (23.44)
Changes across time from intake to 
termination to the FU periods for all 
subjects were significant (F = 12.55, 
p = 001). The interaction of time × 
treatment was not significant 
(F = 1.15, p = 0.32). Comparisons 
were not statistically different at 12 
months
Cannabis use — mean (SD)
MDFT
Intake: 10.41 (11.38)
Termination: 5.12 (8.30)
6-month FU: 5.77 (8.58)
12-month FU: 4.30 (10.15)
CBT
Intake: 11.89 (12.71)
Termination: 9.83 (15.56)
6-month FU: 6.74 (11.95)
12-month FU: 6.41 (11.23)
Both treatments showed 
statistically significant decreases. 
There were no treatment effects for 
30-day frequency of cannabis use
Other drug use — mean (SD)
MDFT
Intake: 1.63 (5.07)
Termination: 0.55 (2.31)
6-month FU: 0.37 (1.56)
12-month FU: 0.14 (0.65)
CBT
Intake: 0.52 (1.41)
Termination: 1.43 (5.97)
6-month FU: 0.32 (1.54)
12-month FU: 1.00 (4.00)
Significant between-treatment 
differences (t = –2.14, p < 0.05, 
d = 0.032)
Alcohol use — mean (SD)
MDFT
Intake: 1.74 (3.20)
Termination: 1.43 (3.61)
6-month FU: 1.70 (5.41)
12-month FU: 2.00 (4.64)
CBT
Intake: 2.66 (7.28)
Termination: 1.61 (3.94)
6-month FU: 0.96 (2.72)
12-month FU: 2.17 (4.73)
Any problems — n (%)
MDFT
Intake: 20 (50)
6-week FU: 5 (12)
Termination: 6 (15)
6-month FU: 4 (10)
12-month FU: 7 (18)
Peer group
Intake: 22 (51)
6-week FU: 17 (40)
Termination: 12 (28)
6-month FU: 14 (33)
12-month FU: 15 (35)
Significant reductions in both 
treatments in the number of youths 
reporting any substance-related 
problems over the 12-month 
follow-up (pseudo-z = –4.29, 
p < 0.001). No treatment effect 
(b = –0.34, pseudo-z = –1.27, ns).
30-day substance use frequency 
— mean (SD)
MDFT
Intake: 0.78 (1.02)
6-week FU: 0.21 (0.56)
Termination: 0.14 (0.54)
6-month FU: 0.22 (0.62)
12-month FU: 0.12 (0.35)
Peer group
Intake: 1.20 (0.98)
6-week FU: 0.75 (0.98)
Termination: 0.95 (1.13)
6-month FU: 0.85 (0.88)
12-month FU: 0.86 (0.88)
Significant reductions in both 
treatments in substance use 
frequency over the 12-month follow-
up. Significant treatment effect 
(b = –0.013, pseudo-z = –3.51, 
p < 0.001, 95 % CI –0.19 to –0.05, 
d = 0.77)
Germany
MDFT
Baseline: 51/59 (86 %)
12-month FU: 26/59 (44 %)
Difference: 42 %
IP
Baseline: 55/61 (90 %)
12-month FU: 43/61 (71 %)
Difference: 19 %
Netherlands
MDFT
Baseline: 37/55 (66 %)
12-month FU: 16/55 (29 %)
Difference: 37 %
IP
Baseline: 37/54 (69 %)
12-month FU: 30/54 (56 %)
Difference: 13 %
Switzerland
MDFT
Baseline: 28/30 (93 %)
12-month FU: 13/30 (43 %)
Difference: 50 %
IP
Baseline: 29/30 (97 %)
12-month FU: 15/30 (50 %)
Difference: 47 %
Total
MDFT
Baseline: 173/212 (82 %)
12-month FU: 81/212 (38 %)
Difference: 44 %
IP
Baseline: 195/238 (82 %)
12-month FU: 124/238 (56 %)
Difference: 30 %
Days of cannabis use in the past 90 
days — mean (SD)
Belgium
MDFT
Baseline: 68.4 (20.6)
3-month FU: 52.3 (30.6)
6-month FU: 51.1 (30.4)
9-month FU: 46.7 (27.3)
12-month FU: 42.5 (29.69)
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Study 1 (Liddle et al., 2001) Study 2 (Liddle et al., 2008) Study 3 (Liddle et al., 2004) Study 4 (CYT) Study 5 (INCANT)
Outcomes Both treatments showed a small 
trend associated with decreases in 
participants as a whole; no 
significant differences between 
treatments
30-day minimal use — n (%)
MDFT
Intake: 8 (7)
Termination: 27 (42)
6-month FU: 28 (42)
12-month FU: 47 (64)
CBT
Intake: 6 (4)
Termination: 23 (39)
6-month FU: 24 (45)
12-month FU: 28 (44)
Significant differences between 
treatments (χ2 = 5.43, p = 0.020).
For the LS class of substance use 
problem severity, results indicated 
that the two treatments showed 
similar effects (treatment coefficient 
for slope = 0.43, SE = 1.17, 
pseudo-z = 0.37, p = 0.712, d = 0.12). 
For the HS class, there were 
significant differences in treatment 
effects, indicating that MDFT 
participants decreased their 
substance use problem severity 
more than CBT participants did 
(holding constant the effects of total 
number of diagnoses and family 
conflict) (treatment coefficient for 
slope = 5.63, SE = 1.95, 
pseudo-z = 2.89, p = 0.004, 95 % CI 
1.73–9.52, d = 1.58). For substance 
use frequency, there were no 
significant differences in treatment 
effects in either class: HS, treatment 
coefficient for slope = 0.32, 
SE = 0.35, pseudo-z = 0.91, 
p = 0.907; LS, treatment coefficient 
for slope = –0.07, SE = 0.54, 
pseudo-z = –0.13, p = 0.916
Any use — n (%)
MDFT
Intake: 18 (45)
6-week FU: 6 (15)
Termination: 4 (10)
6-month FU: 6 (15)
12-month FU: 5 (13)
Peer group
Intake: 31 (72)
6-week FU: 20 (47)
Termination: 21 (49)
6-month FU: 25 (58)
12-month FU: 23 (54)
Significant reductions in both 
treatments in youth reporting any 
substance use over the 12-month 
follow-up. Significant treatment 
effect (b = –0.073, 
pseudo-z = –2.98, p = 0.003, 95 % 
CI 0.24–1.23, OR 2.20)
Frequency of delinquent acts in the 
past 30 days — mean (SD)
MDFT
Intake: 0.80 (1.01)
6-week FU: 0.19 (0.58)
Termination: 0.15 (0.38)
6-month FU: 0.41 (0.73)
12-month FU: 0.36 (0.73)
Peer group
Intake: 0.88 (1.05)
6-week FU: 0.54 (0.95)
Termination: 0.58 (1.03)
6-month FU: 0.68 (1.15)
12-month FU: 0.66 (1.04)
No significant reduction in both 
treatments in frequency of 
delinquency. Significant treatment 
effect with greater decrease in 
MDFT (b = –0.09, pseudo-z = –2.43, 
p < 0.05, 95 % CI –0.17 to –0.02, 
d = 0.31)
IP
Baseline: 66.7 (23.1)
3-month FU: 60.4 (27.5)
6-month FU: 59.7 (29.5)
9-month FU: 52.7 (29.1)
12-month FU: 62.2 (31.5)
Germany
MDFT
Baseline: 58.8 (28.2)
3-month FU: 26.4 (30.5)
6-month FU: 20.1 (27.1)
9-month FU: 21.6 (29.5)
12-month FU: 21.3 (27.1)
IP
Baseline: 62.3 (24.1)
3-month FU: 37.5 (27)
6-month FU: 35.3 (29)
9-month FU: 32.6 (30)
12-month FU: 36.7 (33.6)
France
MDFT
Baseline: 60.2 (24.7)
3-month FU: 38 (31.5)
6-month FU: 39.5 (34.8)
9-month FU: 36.6 (36.1)
12-month FU: 30.9 (32.8)
IP
Baseline: 63.2 (26.8)
3-month FU: 46.4 (31.1)
6-month FU: 36.2 (29.9)
9-month FU: 41.2 (32.9)
12-month FU: 35.2 (29.1)
The Netherlands
MDFT
Baseline: 62.6 (22.7)
3-month FU: 44.1 (32.5)
6-month FU: 37.0 (29.9)
9-month FU: 48.1 (34.3)
12-month FU: 42.4 (34.2)
IP
Baseline: 60.9 (23.7)
3-month FU: 47.1 (32.3)
6-month FU: 46.4 (32)
9-month FU: 47.9 (29.3)
12-month FU: 49 (34.1)
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Study 1 (Liddle et al., 2001) Study 2 (Liddle et al., 2008) Study 3 (Liddle et al., 2004) Study 4 (CYT) Study 5 (INCANT)
Outcomes Any delinquency — n (%)
MDFT
Intake: 19 (48)
6-week FU: 4 (10)
Termination: 6 (15)
6-month FU: 11 (28)
12-month FU: 9 (23)
Peer group
Intake: 22 (51)
6-week FU: 14 (33)
Termination: 14 (33)
6-month FU: 13 (30)
12-month FU: 14 (33)
No significant reduction in both 
treatments in the number of youths 
reporting any delinquent acts
Switzerland
MDFT
Baseline: 47.3 (25)
3-month FU: 47.2 (32.6)
6-month FU: 34.5 (31.7)
9-month FU: 34.8 (32.6)
12-month FU: 39.3 (35.1)
IP
Baseline: 52.2 (29.5)
3-month FU: 44.9 (31.1)
6-month FU: 44.7 (36.1)
9-month FU: 42.3 (35.8)
12-month FU: 39.3 (36.9)
Total
MDFT
Baseline: 59.8 (25.3)
3-month FU: 39.4 (32.5)
6-month FU: 33.9 (31.5)
9-month FU: 35 (33.5)
12-month FU: 34 (32.6)
IP
Baseline: 61.5 (25.4)
3-month FU: 45.2 (30.2)
6-month FU: 41.8 (31.6)
9-month FU: 40.8 (32)
12-month FU: 42.3 (33.8)
Risk of bias
Random sequence 
generation
Unclear* (not described) Unclear (not described) Unclear (not described) Unclear (not described) Low (block randomisation was 
used)
Allocation concealment Unclear (not described) Low Low (a URN randomisation 
programme was used)
Low (a randomly ordered list was 
used)
Low (computer randomisation was 
concealed)
Blinding Low (outcome assessors were 
blinded to treatment condition and 
assessment phase)
Unclear (not described) Low (outcome assessors were 
blinded to treatment assignment 
and to study hypotheses)
Unclear (not described) Low (local researchers were not 
blinded; central outcome assessors 
were blinded to treatment condition)
Incomplete outcome 
data
Unclear (ITT not reported) Unclear (ITT was done but attrition 
is > 20 %)
Unclear (ITT was done but attrition 
was high)
Low (ITT was performed and 
attrition was low)
Unclear (ITT was done and attrition 
is not reported)
Selective reporting Low (outcomes specified in 
measures section also reported in 
results section)
Low (outcomes specified in 
measures section also reported in 
results section)
Unclear (not all outcomes specified 
in measures section also reported in 
results section)
Unclear (not all outcomes specified 
in measures section also reported in 
results section)
Low (all outcomes specified in 
measures section are reported in 
results section)
Other bias Low (no other important source of 
bias could be identified)
Low (no other important source of 
bias could be identified)
Low (no other important source of 
bias could be identified)
Low (no other important source of 
bias could be identified)
Low (no other important source of 
bias could be identified)
* Where the term ‘unclear’ is used, it means that insufficient information is provided by the report.
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I Annex 2
Effects of MDFT compared with other intervention treatments
Outcome AGT MEI CBT
Comparison treatment
Peer group therapy
MET/CB5 ACRA IP
Drug use (alcohol, marijuana and other 
drugs) at 12-month FU
–14.5 % (ns) –29.4 % (p = 0.0006) –57 % (p = 0.001)
Cannabis use at 12-month FU –12.6 % (ns)
Other drug use at 12-month FU –183 % (p > 0.05)
Minimal substance use (no or one occasion 
of alcohol or drug use) at 12-month FU
Relative risk = 1.26 
(p = 0.02)
Abstinence at 12-month FU Odds ratio = 2.20 (95 % CI 
0.77-6.22)
Days of abstinence from cannabis over 12 
months
+6 (ns) +8 (ns)
Percentage meeting criteria for cannabis 
dependence
–14 % (p = 0.015)
Percentage meeting criteria for cannabis 
abuse
–11 %(p = 0.015)
Number of cannabis consumption days over 
12 months
–12 % (p = 0.07)
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I Annex 3
Characteristics of intervention treatments
Description
Intervention
MEI Peer group therapy IP CBT AGT MET/CBT5 ACRA
Type of intervention Family-based, structured 
and psycho-educationally 
focused intervention
Manual-guided 
intervention combining 
education with skills 
training and social 
support
Individual treatment for 
adolescent cannabis 
users, usually used in 
such cases, based on 
counselling and 
motivational interviewing
Individual-based 
intervention over three 
stages
Peer group-based 
semi-structured 
intervention
Five-session intervention 
combining two sessions 
of individual MET with 
three sessions of group 
CBT
Behavioural intervention 
based on individual 
sessions with the 
adolescent
Aim Change parenting 
behaviours and family 
interactions
Develop individual skills 
and promote group 
participation
Improve individual skills 
and strategies for relapse 
prevention. Includes 
elements of CBT
Reduce risky behaviours 
and improve individual 
skills
Develop individual social 
skills such as 
communication, 
self-control, self-
acceptance and problem 
solving, as well as 
building social support 
among group members
Change risky behaviours 
and develop individual 
skills
Teach adolescents new 
ways of handling life’s 
problems without using 
drugs and alcohol
Target Families Adolescents. Four to six 
adolescents participate 
in the groups. Groups are 
open, in that new 
members are admitted 
on a rolling basis as 
previous members 
complete the treatment
Adolescents Adolescents Adolescents Adolescents Adolescents
Intervention format Content-specific group 
discussions, didactic 
presentations that 
include handouts, 
skill-building exercises, 
individual family 
problem-solving within a 
group meeting of several 
families, and homework 
assignments. In case of 
emergency, two 
individual sessions per 
family are available at the 
request of the family of 
the therapist
Worksheets, role-plays, 
handouts, videotapes 
and group discussions
Sessions are individual, 
with the adolescent. 
Parents may be seen 
alone, or in groups, purely 
for reasons of drug 
education and mutual 
support
Phase 1 determines and 
prioritises adolescents’ 
problems and constructs 
the treatment contract. 
Phase 2 is aimed at 
increasing coping 
competence and 
reducing risky 
behaviours. Phase 3 
focuses on relapse 
prevention
Didactic presentations, 
group discussions, group 
skill-building exercises 
and homework 
assignments
Brief didactic 
presentations, modelling, 
role-playing and 
homework assignments. 
Intervention begins with 
two individual MET 
sessions aimed at 
explaining treatment 
expectations, assessing 
and building motivation 
for change and preparing 
the adolescent for the 
group sessions. In 
sessions 3, 4 and 5, the 
adolescent joins a group 
of five or six adolescents 
for CBT skills training
Ten sessions with the 
adolescent alone and 
four sessions with 
caregivers (two with the 
caregivers alone and two 
with the caregivers along 
with the adolescent). 
First, the therapist 
assesses the 
adolescent’s triggers for 
substance use and their 
satisfaction with life. 
Second, the treatment 
plan is completed.
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Description
Intervention
MEI Peer group therapy IP CBT AGT MET/CBT5 ACRA
Intervention content Learning alternative 
forms of stress reduction, 
understanding family and 
individual risk and 
protective factors, 
improving family 
organisation, information 
on rules and limit-setting, 
and improving family 
communication and 
problem-solving abilities.
Each session is 
structured in three parts: 
(1) didactic presentation 
(informal and 
conversional vs. formal 
lecture) by the therapist; 
(2) topic-focused 
intrafamily and/or 
interfamily group 
discussion; and (3) 
skill-building exercises. 
Families receive 
workbooks with content 
summaries of the 
session goals and 
activities
Exploring beliefs about 
drugs, understanding the 
roots and triggers of drug 
use, re-evaluating and 
eventually avoiding 
friends who use drugs, 
improving refusal 
techniques, recognising 
automatic thoughts 
about drug use and 
increasing prosocial, 
non-drug-related ways to 
have fun and feel good 
and other relapse 
prevention methods
Coping with stress, 
managing anger, 
increasing assertiveness 
in interpersonal contacts 
and addressing negative 
thoughts about 
substance use
In phase 1 parents attend 
the first two sessions to 
support the adolescent’s 
participation in 
treatment.
Phase 2 provides 
information and 
education, contingency 
contracting, information 
on self-monitoring, 
problem-solving training, 
communication skills 
training, information on 
identifying cognitive 
distortions and on 
increasing healthy 
recreational activities, 
and homework 
assignments
Phase 1 includes two 
individual family sessions 
to enlist cooperation and 
parental support, outline 
the goals and format of 
the treatment, and 
discuss group rules and 
procedures. The 
therapists also have an 
individual meeting with 
each teenager. Phase 2 
has four structured AGT 
sessions to facilitate trust 
and self-disclosure 
among adolescents and 
establish group identity. 
Phase 3 is the 
adolescents’ social skills 
building phase, aimed at 
developing drug refusal, 
improving conflict 
resolution and anger 
management skills, 
improving 
communication and 
problem solving with 
parents, peers and other 
adults, and developing 
pro social interests and 
behaviours. Phase 4 
focuses on the 
generalisation and 
maintenance of new 
skills
Developing refusal skills 
and a positive social 
support network, 
reducing association 
with substance-using 
peers, planning for 
unanticipated high-risk 
situations and coping 
with relapse
Skills training and 
practice in relapse 
prevention, 
communication, 
problem-solving and 
prosocial recreation, 
communication and 
motivation
Duration 90-minute weekly 
sessions over a 16-week 
period
One therapist-led 
session in the 12–16 
weeks of treatment. The 
intervention includes six 
modules, each 
approximately 2 weeks 
long
Each session is 
administered once a 
week over a period of 
4–6 months (60- to 
90-minute sessions)
Groups of between six 
and eight adolescents 
are led by two therapists 
for 90 minutes
Therapist’s role Educator and facilitator 
of inter- and intrafamily 
communication 
processes
Active and directive, but 
not confrontational
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Description
Intervention
MEI Peer group therapy IP CBT AGT MET/CBT5 ACRA
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I Annex 4
1. (substance-related disorders) MeSH terms
2. (abus* or use or misuse or depend* or addict*) ti, ab
3. 1 or 2
4. (treatment or therapy) ti, ab
5. (adolescent) MeSH terms
6. (adolescent* or teen* or youth or “young people”) ti, ab
7. 5 or 6
8. (MDFT or multidimensional family therapy or multi-dimensional family therapy or multidimensional family therapy) ti, ab
9. 3 and 4 and 7 and 8
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